Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin
- PMID: 16455939
- PMCID: PMC1392696
- DOI: 10.1128/JCM.44.2.655-656.2006
Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin
Abstract
Daptomycin, a new cyclic lipopeptide, was recently approved for the treatment of infections by gram-positive organisms, including infections with methicillin-resistant Staphylococcus aureus (MRSA). A patient infected with infected with MRSA developed resistance to daptomycin after prolonged exposure, which resulted in clinical failure. Clinicians should be aware of the possibility of daptomycin resistance and should consider routine testing for daptomycin susceptibility.
References
-
- Mangili, A., I. Bica, D. R. Snydman, and D. H. Hamer. 2005. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 40:1058-1060. - PubMed
-
- Richter, S. S., D. E. Kealey, C. T. Murray, K. P. Heilmann, S. L. Coffman, and G. V. Doern. 2003. The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species. J. Antimicrob. Chemother. 52:123-127. - PubMed
-
- Rybak, M. J., E. Hershberger, T. Moldovan, and R. G. Grucz. 2000. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob. Agents Chemother. 44:1062-1066. - PMC - PubMed
-
- Steenbergen, J. N., J. Alder, G. M. Thorne, and F. P. Tally. 2005. Daptomycin: a lipopeptide antibiotic for the treatment of serious gram-positive infections. J. Antimicrob. Chemother. 55:283-288. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
